You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of July 29, 2019

  • Discovery Projects
  • Phase 1
    35
  • Phase 2
    34
  • Phase 3
    23
  • Registration
    9
  • Total101
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY meningococcal infections Phase 1 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection Phase 1 New Molecular Entity Vaccine
PF-06936308
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Multiple Cancers Phase 1 New Molecular Entity Vaccine
recifercept
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Soluable recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy
Go to clinical trial
Achondroplasia (Biologic)
Project advanced
Phase 1 New Molecular Entity Biologic
PF-06939926
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
minidystrophin
Go to clinical trial
Duchenne Muscular Dystrophy (Biologic) (ORPHAN - U.S., E.U.) Phase 1 New Molecular Entity Biologic
PF-06882961
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Go to clinical trial
Diabetes Mellitus-Type 2 Phase 1 New Molecular Entity Small Molecule
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Go to clinical trial
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Factor Blocker
Go to clinical trial
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ PF-04518600 (OX40) and PF-05082566 (anti-4-1BB/CD137) for Cancer (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Cancer (Biologic) Phase 1 Product Enhancement Biologic
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
pan-PI3K/mTOR inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Combo w/ gedatolisib (PF-05212384) for Cancer Phase 1 Product Enhancement Small Molecule
Inlyta (axitinib)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
VEGF Tyrosine Kinase Inhibitor
Go to clinical trial
Combo w/ Merck's Keytruda� (PD-1, pembrolizumab) for: Cancer Phase 1 Product Enhancement Small Molecule
PF-04447943
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
PDE9 Inhibitor
Go to clinical trial
Sickle Cell Anemia (ORPHAN - U.S.) Phase 1 New Molecular Entity Small Molecule
PF-04518600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
OX40 receptor Agonist
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-05230907
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Factor Xa Protein Replacement
Go to clinical trial
Intracerebral Hemorrhage (Biologic) (ORPHAN - U.S.) Phase 1 New Molecular Entity Biologic